CHARLES LEMAISTRE and HANS MARK were named chancellors emeriti of the University of Texas System Board of Regents.
THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY named the winners of the society's annual awards, which will be presented Sept. 26 at the ESMO 2014 Congress in Madrid.
JENNIFER ZEITZER was named deputy director of the Office of Public Affairs of the Federation of American Societies for Experimental Biology.
RICHARD DAVID was named a clinical professor of urology, voluntary, at the David Geffen School of Medicine at the University of California, Los Angeles.
MICHAEL BOOKMAN will join Arizona Oncology, a practice in The US Oncology Network, and will serve as medical director of the US Oncology Research Gynecology Research Program, effective Oct. 6.
DAVID ESPEY stepped down as acting director of the CDC Division of Cancer Prevention and Control, a position he has held since Feb. 3.
RICHARD WAHL was named the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis. He also will serve as director of the Mallinckrodt Institute of Radiology. He will begin in October.
MD ANDERSON CANCER CENTER announced a partnership with Hospital Israelita Albert Einstein in Brazil.
THE ASSOCIATION OF COMMUNITY CANCER CENTERS launched an online oncology drug database with information on drug coding, billing and reimbursement.
FDA and the European Medicines Agency both granted orphan drug designations to ABT-414, an investigational anti-epidermal growth factor receptor antibody drug conjugate developed by AbbVie. The compound is being evaluated for safety and efficacy in patients with glioblastoma multiforme.
